Vascular Biogenics LTD. – Ordinary Shares (NASDAQ:VBLT) Sellers Reduced By 17.44% Their Shorts

June 27, 2018 - By Alex Paulin

Vascular Biogenics Ltd. (NASDAQ:VBLT) Corporate Logo

Vascular Biogenics LTD. – Ordinary Shares (NASDAQ:VBLT) showed a decrease of 17.44% in shorted shares. FINRA announced shorted shares of VBLT’s total 436,600 shares. That’s 17.44% down from 528,800 shares. 4 days will cost VBLT with 116,500 average volume to recover its former position. 3.07% is Vascular Biogenics LTD. – Ordinary Shares float short.

The stock decreased 1.08% or $0.03 during the last trading session, hitting $2.3.Vascular Biogenics Ltd. has volume of 30,895 shares. Since June 27, 2017 VBLT has declined 60.91% and is downtrending. VBLT underperformed the S&P 500 by 73.48%.

Vascular Biogenics Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer.The firm is worth $68.76 million. The company??s program is based on its proprietary vascular targeting system platform technology, which utilizes genetically targeted therapy to destroy newly formed or angiogenic blood vessels.Currently it has negative earnings. The Company’s lead product candidate is VB-111, a gene biologic that is in Phase III clinical trials for the treatment of recurrent glioblastoma, an aggressive form of brain cancer; and has completed Phase II clinical trials for recurrent platinum-resistant ovarian cancer, as well as for iodine-resistant differentiated thyroid cancer.

Vascular Biogenics Ltd. (NASDAQ:VBLT) Ratings Coverage

Total analysts of 4 have positions in Vascular Biogenics (NASDAQ:VBLT) as follows: 0 rated it a “Buy”, 0 with “Sell” and 4 with “Hold”. The positive are 0. Since March 8, 2018 according to StockzIntelligence Inc Vascular Biogenics has 6 analyst reports. On Thursday, March 8 the firm has “Neutral” rating by H.C. Wainwright given. On Friday, May 18 H.C. Wainwright maintained Vascular Biogenics Ltd. (NASDAQ:VBLT) with “Hold” rating. On Thursday, March 8 the rating was downgraded by Piper Jaffray to “Hold”. On Thursday, March 22 the firm has “Hold” rating by H.C. Wainwright given. On Friday, March 9 the company was downgraded by Chardan Capital Markets. On Thursday, March 8 the rating was downgraded by JMP Securities to “Hold”.

For more Vascular Biogenics Ltd. (NASDAQ:VBLT) news brought out recently go to: Schaeffersresearch.com, Seekingalpha.com, Streetinsider.com, Streetinsider.com or Streetinsider.com. The titles are as follows: “3 Surging Penny Stocks” brought out on June 06, 2018, “VBL Therapeutics +42% after presenting data on MOSPD2 platform” on June 05, 2018, “VBL Therapeutics (VBLT) Prices 5.9M Share Registered Direct Offering at $2.50/Sh” with a publish date: June 26, 2018, “Pre-Open Movers 06/06: (AXON) (VBLT) (SIG) Higher; (AMBA) (IMGN) (OLLI) Lower (more…)” and the last “VBL Therapeutics (VBLT) Presents Positive Data on its MOSPD2 Platform Technology” with publication date: June 05, 2018.

Vascular Biogenics Ltd. (NASDAQ:VBLT) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.